Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORINYL 1+50 21-DAY vs ESTARYLLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norinyl 1+50 21-Day contains norethindrone (a progestin) and mestranol (an estrogen). Mestranol is converted to ethinyl estradiol, which provides negative feedback on gonadotropin release, inhibiting ovulation. Norethindrone suppresses gonadotropins and alters cervical mucus and endometrial lining to prevent implantation.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
Prevention of pregnancy
FDA-approved: Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.,Off-label: Acne vulgaris (for norgestimate-containing pills), management of menstrual disorders (e.g., dysmenorrhea, abnormal uterine bleeding), hormone therapy for transgender women (non-standardized).,Note: Off-label uses are not FDA-approved for this specific formulation.
One tablet (1 mg norethindrone + 0.05 mg mestranol) orally once daily for 21 days, followed by 7 placebo tablets. Start on day 1 of menstrual cycle or first Sunday after onset.
One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.
Norethindrone: 5-8 hours; Ethinyl estradiol: 7-15 hours; steady-state reached within 5-7 days
Terminal elimination half-life of ethinyl estradiol is approximately 13-16 hours; clinical context: steady-state achieved within 5-7 days
Mestranol is demethylated to ethinyl estradiol; ethinyl estradiol and norethindrone are metabolized by CYP3A4. Conjugation (glucuronidation and sulfation) occurs in the liver and gut wall.
Ethinyl estradiol is primarily metabolized by CYP3A4, with conjugation to glucuronides and sulfates. Norgestimate is rapidly metabolized to its active metabolite, norelgestromin, and further to levonorgestrel; involvement of CYP2C19 and CYP3A4 in norgestimate metabolism is noted.
Renal (40% as metabolites), fecal (50% as metabolites), <1% unchanged
Renal: ~55% as metabolites, ~27% unchanged; Fecal: ~45% as metabolites
Norethindrone: ~80% bound to SHBG and albumin; Ethinyl estradiol: ~97% bound to albumin, 2-3% free
Ethinyl estradiol: 97-98% bound to albumin, with minor binding to sex hormone-binding globulin
Norethindrone: Vd approximately 4 L/kg; Ethinyl estradiol: Vd approximately 2.5 L/kg; indicates extensive tissue distribution
Ethinyl estradiol: approximately 2.8 L/kg; indicates extensive tissue distribution
Oral: Norethindrone ~90%; Ethinyl estradiol ~97-98% (due to low first-pass metabolism)
Oral: approximately 55% due to first-pass metabolism; consistent in healthy females
No dosage adjustment required for mild-to-moderate renal impairment. Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of fluid retention and hyperkalemia.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in severe renal impairment or end-stage renal disease due to lack of data.
Contraindicated in acute hepatitis, severe cirrhosis (Child-Pugh class C), or liver tumors. Dose adjustment not recommended for mild hepatic impairment (Child-Pugh A) but use with caution; avoid in moderate-to-severe impairment (Child-Pugh B or C).
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; dose adjustment not specifically defined, but alternative contraception recommended.
Not indicated in pediatric females before menarche. For postmenarchal adolescents, dose same as adults: one tablet orally once daily for 21 days.
Approved for use in postmenarchal adolescents: same dosing as adults (one tablet daily for 21 days, then 7 days placebo). No weight-based dosing required.
Not indicated in postmenopausal women due to lack of efficacy and increased risk of thromboembolic events, cardiovascular disease, and malignancy.
Not indicated in postmenopausal women. No specific geriatric dosing; contraindicated in women over 60 years due to increased thromboembolic risk.
Cigarette smoking increases risk of serious cardiovascular side effects from combined oral contraceptives. Risk increases with age (especially >35 years) and with heavy smoking (≥15 cigarettes/day). Women should not use combined oral contraceptives if they smoke and are over 35 years old.
Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptives. This risk increases with age (especially in women over 35 years of age) and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Carcinoma of reproductive organs (breast, endometrium),Hepatic adenoma or liver tumors,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Bleeding irregularities (breakthrough bleeding, amenorrhea),Ocular lesions (optic neuritis, retinal thrombosis),Possible migraine exacerbation
Thrombotic disorders: Increased risk of venous thromboembolism (VTE) and arterial thromboembolism (e.g., MI, stroke). Discontinue if thrombotic event occurs.,Cardiovascular disease: Avoid in women with uncontrolled hypertension, diabetes with vascular involvement, or history of thromboembolic disease.,Cigarette smoking: Strongly advise cessation, especially in women over 35.,Liver disease: Discontinue if jaundice or cholestasis develops; contraindicated in acute viral hepatitis or severe cirrhosis.,Hormone-dependent malignancies: Increased risk of breast cancer (current use) and cervical cancer; avoid if known or suspected breast cancer.,Gallbladder disease: Increased risk of gallstones.,Carbohydrate and lipid metabolism: Monitor glucose and lipids in predisposed patients; may impair glucose tolerance and increase triglycerides.,Headache: Evaluate if new-onset or worsening migraine, especially with focal neurological symptoms.,Uterine bleeding: Rule out pregnancy if amenorrhea occurs; irregular bleeding may require evaluation.,Depression: Monitor for mood changes; discontinue if severe depression recurs.,Angioedema: Risk in women with hereditary angioedema.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Endometrial carcinoma,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy
Known or suspected pregnancy,Current or past venous thrombosis (e.g., deep vein thrombosis, pulmonary embolism),Current or past arterial thrombosis (e.g., myocardial infarction, stroke) or prodromal conditions (e.g., angina, transient ischemic attack),Known thrombophilic disorders (e.g., Factor V Leiden, prothrombin mutation, antithrombin deficiency),History of cerebrovascular or coronary artery disease,Uncontrolled hypertension (sustained >160/100 mm Hg),Diabetes mellitus with nephropathy, retinopathy, neuropathy, or other vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura) in women over 35,Current or past breast cancer, or other estrogen- or progestin-sensitive cancer,Active liver disease (e.g., acute viral hepatitis, severe cirrhosis) or benign/malignant liver tumors,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component of Estarylla,Use of highly active antiretroviral therapy (HAART) containing ritonavir or direct-acting antivirals for hepatitis C (e.g., ombitasvir/paritaprevir/ritonavir) due to potential for hepatotoxicity
Grapefruit juice may inhibit CYP3A4 metabolism, increasing ethinyl estradiol levels and potential adverse effects (nausea, breast tenderness, thromboembolism). St. John's Wort may decrease contraceptive efficacy. No significant interactions with other foods.
There are no known significant food interactions. Grapefruit juice may increase estrogen levels but clinical significance is unclear; consider moderate intake.
FDA Pregnancy Category X. First trimester: Use is contraindicated due to increased risk of congenital anomalies, particularly cardiovascular and limb defects. Second and third trimesters: Associated with masculinization of female fetuses (pseudohermaphroditism) due to androgenic activity of norethindrone. Estrogen component may cause fetal harm. Discontinue immediately if pregnancy occurs.
Estarylla (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive. Use during pregnancy is contraindicated. First trimester: No strong evidence of major malformations from inadvertent exposure, but increased risk of cardiovascular and limb defects in some studies. Second and third trimesters: Associated with fetal harm, including cardiovascular effects (e.g., congenital heart defects) and possible estrogenic effects, though data are limited. Postnatal effects: Potential long-term developmental effects unknown. Overall risk is low but not zero; avoid use in pregnancy.
Contraindicated in breastfeeding. Norethindrone and ethinyl estradiol are excreted in breast milk; M/P ratio for norethindrone is approximately 0.5. May reduce milk volume and quality. Known adverse effects include jaundice and breast enlargement in infants. Avoid use during lactation.
Estarylla is excreted in breast milk in small amounts (ethinyl estradiol: M/P ratio ~0.2; levonorgestrel: M/P ratio ~0.3-0.4). Combined hormonal contraceptives may reduce milk production and affect milk composition, especially in early postpartum. Use is generally not recommended until breastfeeding is well-established (at least 6 weeks postpartum). For later use, progestin-only methods are preferred. Monitor infant for jaundice and growth.
Not applicable; use is contraindicated during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered hepatic metabolism) could reduce efficacy of oral contraceptives, but no dose adjustments are warranted as the drug should not be used.
Estarylla is contraindicated in pregnancy. No dosing adjustments are recommended because it should not be used. Pregnancy alters pharmacokinetics of oral contraceptives (e.g., increased volume of distribution, altered hepatic metabolism), but no dose changes are indicated due to contraindication. If inadvertently taken, discontinue immediately.
For combination oral contraceptives (COCs) like NORINYL 1+50, counsel patients that concurrent use of CYP3A4 inducers (e.g., rifampin, certain anticonvulsants) may reduce contraceptive efficacy. Advise backup contraception or alternate method. Norethindrone 1 mg/ethinyl estradiol 50 mcg has higher estrogen content; consider increased thromboembolism risk vs low-dose pills. Monitor for hypertension, migraine with aura, and breakthrough bleeding patterns.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It is indicated for prevention of pregnancy. Monitor for thromboembolic events, especially in smokers over 35. Counsel on missed dose management: take as soon as remembered, use backup contraception if more than 24 hours late. May reduce menstrual cramps and acne. Not recommended in patients with history of estrogen-dependent neoplasia, liver disease, or uncontrolled hypertension.
Take one tablet daily at the same time, with or without food. Follow pack directions: 21 active pills then 7 placebo days.,Expect withdrawal bleeding during placebo week; if no bleed occurs, consider pregnancy test.,Missed pill: if delayed <12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days.,Common side effects: nausea, breast tenderness, headache; usually improve within 3 months.,Report severe leg pain/chest pain/sudden dyspnea/speech changes as possible signs of blood clot.,Avoid grapefruit juice as it may increase estrogen levels and side effects.,Does not protect against STIs; use condoms for prevention.
Take one pill daily at the same time each day.,If you miss a pill, take it as soon as remembered; use backup contraception if more than 24 hours late.,Do not smoke while taking this medication, especially if over 35.,Report any signs of blood clots: leg pain, chest pain, shortness of breath, or sudden vision changes.,This medication does not protect against HIV or other STDs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORINYL 1+50 21-DAY vs ESTARYLLA, answered by our medical review team.
NORINYL 1+50 21-DAY is a Combined Oral Contraceptive that works by Norinyl 1+50 21-Day contains norethindrone (a progestin) and mestranol (an estrogen). Mestranol is converted to ethinyl estradiol, which provides negative feedback on gonadotropin release, inhibiting ovulation. Norethindrone suppresses gonadotropins and alters cervical mucus and endometrial lining to prevent implantation.. ESTARYLLA is a Combined Oral Contraceptive that works by Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORINYL 1+50 21-DAY and ESTARYLLA depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORINYL 1+50 21-DAY is: One tablet (1 mg norethindrone + 0.05 mg mestranol) orally once daily for 21 days, followed by 7 placebo tablets. Start on day 1 of menstrual cycle or first Sunday after onset.. The standard adult dose of ESTARYLLA is: One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORINYL 1+50 21-DAY and ESTARYLLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORINYL 1+50 21-DAY is classified as Category C. FDA Pregnancy Category X. First trimester: Use is contraindicated due to increased risk of congenital anomalies, particularly cardiovascular and limb defects. Second and third trim. ESTARYLLA is classified as Category C. Estarylla (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive. Use during pregnancy is contraindicated. First trimester: No strong evidence of major malformations f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.